- Home
- PCB vs CMPX Comparison
PCB vs CMPX Comparison
Compare PCB & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCB
- CMPX
- Stock Information
- Founded
- PCB 2003
- CMPX 2014
- Country
- PCB United States
- CMPX United States
- Employees
- PCB N/A
- CMPX N/A
- Industry
- PCB Major Banks
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- PCB Finance
- CMPX Health Care
- Exchange
- PCB Nasdaq
- CMPX Nasdaq
- Market Cap
- PCB 264.4M
- CMPX 214.6M
- IPO Year
- PCB N/A
- CMPX N/A
- Fundamental
- Price
- PCB $19.47
- CMPX $2.60
- Analyst Decision
- PCB Hold
- CMPX Strong Buy
- Analyst Count
- PCB 2
- CMPX 4
- Target Price
- PCB $22.00
- CMPX $13.75
- AVG Volume (30 Days)
- PCB 24.0K
- CMPX 2.2M
- Earning Date
- PCB 01-31-2025
- CMPX 11-12-2024
- Dividend Yield
- PCB 3.70%
- CMPX N/A
- EPS Growth
- PCB N/A
- CMPX N/A
- EPS
- PCB 1.68
- CMPX N/A
- Revenue
- PCB $94,833,000.00
- CMPX $850,000.00
- Revenue This Year
- PCB N/A
- CMPX N/A
- Revenue Next Year
- PCB $10.40
- CMPX $613.39
- P/E Ratio
- PCB $11.59
- CMPX N/A
- Revenue Growth
- PCB N/A
- CMPX N/A
- 52 Week Low
- PCB $14.50
- CMPX $0.77
- 52 Week High
- PCB $22.20
- CMPX $2.70
- Technical
- Relative Strength Index (RSI)
- PCB 44.81
- CMPX 76.97
- Support Level
- PCB $18.14
- CMPX $1.43
- Resistance Level
- PCB $19.85
- CMPX $2.70
- Average True Range (ATR)
- PCB 0.56
- CMPX 0.29
- MACD
- PCB -0.00
- CMPX 0.12
- Stochastic Oscillator
- PCB 56.84
- CMPX 92.31
About PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.